Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.



COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Confirmed Cases
10,747
Total counts of COVID-19 confirmed patients.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 881 1,344 10,787
          North America 458 763 7,075
          Europe 235 304 2,198
          Asia Pacific 32 40 146
          Latin America 96 160 690
          SWAAC 60 77 678
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
6,451
COVID-19
In-hospital Mortality
50%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 6451 5140
Age(years)
Median(IQR) 47(37,55) 48(38,56)
# observed 6451 5140
BMI, kg/m2
Median(IQR) 33(29,39) 34(29,39)
# observed 6124 4883
Sex
Male 68%(4384) 69%(3559)
Female 32%(2067) 31%(1581)
# observed 6451 5140
Race/Ethnicity
Black 14%(918) 14%(707)
White (Non-Hispanic) 41%(2669) 41%(2102)
Asian 3%(225) 4%(181)
Mid East, N African 1%(65) 1%(53)
Other 4%(248) 4%(195)
Unknown 5%(338) 5%(270)
Multiple 4%(271) 4%(224)
Hispanic 27%(1717) 27%(1408)
# observed 6451 5140
Pre-ECMO Comorbidities
No comorbidity 19%(1242) 18%(933)
Cancer 2%(110) 2%(81)
Pregnancy 4%(249) 4%(191)
Immunocompromised 4%(261) 4%(199)
Diabetes 30%(1912) 30%(1566)
Pre-existing heart disease 4%(245) 3%(145)
Pre-existing lung disease 4%(248) 4%(195)
Pre-existing renal insuff. 3%(195) 3%(150)
Frailty 1%(35) 0%(21)
Asthma 12%(783) 12%(623)
BMI 57%(3704) 59%(3044)
Hypertension 35%(2272) 36%(1855)
# observed 6451 5140
Acute illness
ARDS 84%(5427) 100%(5140)
Acute heart failure 7%(442) 5%(235)
Myocarditis 2%(123) 0%(22)
Acute kidney injury 27%(1727) 28%(1419)
# observed 6451 5140
Pre-ECMO Cardiac Arrest
Yes 6%(368) 3%(162)
No 94%(5980) 97%(4901)
# observed 6348 5063
Pre-ECMO Co-Infection
No Co-infection 50%(3214) 48%(2456)
Bacterial pneumonia 44%(2832) 46%(2377)
Co-viral infection 9%(610) 9%(455)
Blood stream infection 16%(1061) 18%(911)
Urinary tract infection 8%(512) 9%(446)
# observed 6450 5139

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 6451 5140
Noninvasive ventilation
Noninvasive ventilation prior to intubation 78%(5024) 80%(4104)
BiPAP 45%(2921) 46%(2371)
CPAP 8%(486) 8%(394)
HFNC 54%(3502) 56%(2885)
# observed 6451 5140
Pre-ECLS intubation (days)
Median(IQR) 2.7(0.7,5.8) 3.1(1.0,6.0)
# observed 5553 4425
Ventilator mode
Conventional 96%(5466) 96%(4416)
# observed 5714 4577
PEEP, cm H2O
Median(IQR) 14.0(12.0,16.0) 14.0(12.0,16.0)
# observed 5167 4198
PIP, cm H2O
Median(IQR) 34.0(30.0,38.0) 35.0(31.0,39.0)
# observed 3987 3205
FiO2
Median(IQR) 1.00(1.00,1.00) 1.00(1.00,1.00)
# observed 5001 4010
PaO2/FiO2
Median(IQR) 71(58,93) 71(58,91)
# observed 4858 3900
PCO2
Median(IQR) 60(49,74) 61(50,75)
# observed 5173 4135
Pre-ECMO Support
Prone positioning 52%(3307) 56%(2863)
# observed 6393 5099
Neuromuscular blockers 73%(4679) 77%(3932)
# observed 6394 5100
Inhaled pulmonary vasodilators 39%(2475) 42%(2119)
# observed 6393 5099
Any vasoactive support 54%(3447) 53%(2718)
# observed 6391 5098
Norepinephrine 47%(3017) 48%(2449)
# observed 6391 5098
Therapies, Immunomodulators
Any therapy 94%(6034) 95%(4885)
Glucocorticoids 81%(5226) 82%(4237)
IVIG 2%(156) 2%(84)
Anti-cytokine 25%(1611) 26%(1352)
Lopinavir/Ritonavir 1%(47) 1%(43)
JAK inhibition 2%(127) 2%(110)
Chloroquine/hydroxychloroquine 9%(611) 10%(513)
Remdesivir 67%(4330) 69%(3544)
# observed 6451 5140
Support type
Respiratory 94%(6086) 100%(5126)
Cardiac 4%(287) 0%(6)
ECPR 1%(78) 0%(8)
# observed 6451 5140

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 24%(1574) 23%(1169)
Discharged alive to long-term acute care or unspecified location 15%(947) 16%(809)
Discharged to another hospital 6%(409) 6%(329)
Remain in the hospital (discharged from ICU) 0%(12) 0%(11)
Remain in the ICU 4%(279) 4%(227)
In-hospital death 50%(3230) 50%(2595)
Hours on ECMO 610 642
Tracheostomy 46%(2668) 50%(2286)
# observed 5755 4614
Select complications
Seizures 1%(44) 1%(34)
# observed 6280 5009
CNS infarction by US/CT/MRI 2%(100) 1%(69)
# observed 6280 5009
CNS hemorrhage by US/CT/MRI 7%(458) 7%(374)
# observed 6280 5009
Hemolysis 9%(593) 9%(467)
# observed 6280 5009
Oxygenator failure 18%(1152) 20%(1007)
# observed 6280 5009
Pump failure 1%(89) 2%(78)
# observed 6280 5009
Circuit change 15%(917) 15%(773)
# observed 6280 5009
Thrombosis/Clots in circuit component 3%(189) 3%(155)
# observed 6280 5009
Discharge location
Home 29%(852) 27%(623)
Transfer to LTAC or Rehab 8%(222) 9%(201)
Transfer to another hospital 14%(409) 14%(329)
Other/Unknown 3%(76) 2%(56)
*N/A - Data elements with n<5 are not displayed.

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].

We’ve updated our Privacy Policy. By continuing to use this Service, you acknowledge you’ve read the updated Privacy Policy.